Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors

Bruno Bastos

Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors

Bruno Bastos

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - May 20 2020
Event	Journal of Clinical Oncology - Duration: May 20 2020 → …

Conference

Conference	Journal of Clinical Oncology
Period	5/20/20 → …

Cite this

@conference{5a2f31ac64e141bdad846a9fb42a51e2,

title = "Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors",

author = "Bruno Bastos",

note = "Journal of Clinical Oncology (2020) 38(15 Supp):3507-3507; Journal of Clinical Oncology ; Conference date: 20-05-2020",

year = "2020",

month = may,

day = "20",

language = "American English",

}

TY - CONF

T1 - Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors

AU - Bastos, Bruno

N1 - Journal of Clinical Oncology (2020) 38(15 Supp):3507-3507

PY - 2020/5/20

Y1 - 2020/5/20

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/3875

M3 - Presentation

T2 - Journal of Clinical Oncology

Y2 - 20 May 2020

ER -

Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors

Conference

Other files and links

Cite this